Mandate

Vinge has advised Main Capital and Alfa eCare in connection with their strategic acquisition of Joliv

The Alfa eCare group is a recognized eHealth software company, providing solutions to both public and private healthcare providers throughout Sweden.

Joliv provides a range of eHealth solutions servicing over 120 clients primarily in the elderly care market. Joliv’s solutions contribute to a safe and quality-assured work environment for care providers with reduced administration needs and more time for personal meetings with patients. The strategic merge creates a one-stop-shop offering for the Swedish care market helping care providers and municipalities to further improve the quality of care provision.
 
Vinge’s team consisted of Filip Öhrner, Kristina Ekberg, Jesper Lindvall, Jonathan Riddersholm, Ellen Åkerdahl Flygt (M&A), Ebba Svenburg (Employment), Karl-Hugo Engdahl (Agreements and GDPR/IT), Stojan Arnerstål (IPR), Mikael Ståhl, Axel Jansson (Banking and Finance), Carl Bruneheim and Nathalie Hughes (VDR Assistants).

 

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025